Randox Health to sponsor Aintree’s Becher Chase
Randox Health to sponsor Aintree’s Becher Chase
Randox is pleased to announce that Randox Health will be sponsoring the Becher Chase at Aintree Racecourse in a three-year deal.
The £145,000 Randox Health Becher Chase is the centrepiece of Becher Chase Day at Aintree on Saturday, December 9, the only fixture outside of the Randox Health Grand National Festival to feature action over the Grand National fences.
Dr Peter FitzGerald, founder and Managing Director of Randox Health, emphasised Randox Health‘s commitment to both racing and the city of Liverpool.
He said: “We’re delighted to sponsor the Becher Chase, which year-on-year is becoming a more prominent day in the racing calendar for high-calibre horses to compete. With the ongoing work being done by the team at Aintree, that’s no surprise.
“Aintree is a spectacular course and though we will obviously miss the return of One For Arthur, having an open field as we begin the run up to the most exciting race in the whole calendar – the 2018 Randox Health Grand National – will add an unexpected frisson for racing fans.”
As previously announced, Aintree’s Listed Chase over three miles and a furlong on Becher Chase Day, won last year by Many Clouds, has been re-named in honour of the 2015 Grand National winner and upgraded from Listed to Grade 2 level. It will be run as the £50,000 G2 188Bet.co.uk Many Clouds Chase.
John Baker, Managing Director of Aintree Racecourse, added: “We’re thrilled that Randox Health has decided to extend their sponsorship of the Grand National by adding the Becher Chase as well.
“Randox is a committed, valued and exciting partner for Aintree and Jockey Club Racecourses and we look forward to working closely with the team at Randox for many years to come.
“Becher Chase Day is going from strength to strength and with the quality of horses entered in both the Becher and Sefton Chase in recent years, we’re confident it’s going to be another fantastic day over the iconic Grand National fences at Aintree.”
The G3 Randox Health Becher Chase is a handicap chase over three and a quarter miles of the Grand National course. It serves as an early-season trial for the Randox Health Grand National.
Two winners have gone on to win the Grand National; Amberleigh House and Silver Birch. Earth Summit won the race in 1998 following his Grand National win the previous season.
The second race of the day over the Grand National fences on Becher Chase Day is the £70,000 188bet.co.uk Grand Sefton Handicap Chase over two miles and five furlongs.
In addition to Randox Health’s sponsorship of the Becher Chase and after a successful partnership for Sandown Park Racecourse’s Gents Day this summer, the company will also sponsor the Henry VIII Novices’ Chase at the Esher venue on Saturday, December 9. This is part of the three year agreement with Jockey Club Racecourses to sponsor Becher Chase day.
Entries for the 2017 Randox Health Becher Chase, plus the 188bet Grand Sefton Chase, which also takes place over the Grand National fences, close at noon today Tuesday, November 14 and will be revealed tomorrow, Wednesday, November 15.
Tickets for the 2017 Randox Health Becher Chase raceday are available to purchase at aintree.thejockeyclub.co.uk or by calling 0344 579 3001. Racegoers can also buy tickets directly from the sales office at Aintree Racecourse. Hospitality packages are currently available to purchase, please call 0151 522 2911 for more information.
The Risk of Gestational Diabetes to Women ā World Diabetes Day
Every year, Randox Reagents support World Diabetes Day on the 14th November. This year, the theme is ‘Women and diabetes – our right to a healthy future’ with the International Diabetes Federation running a campaign aiming to provide all women with diabetes with affordable and equitable access to care and education to better manage their diabetes and improve their health outcomes. A type of diabetes that affects women is gestational diabetes.
Gestational diabetes – what is it?
Gestational Diabetes Mellitus (GDM) is a form of diabetes which appears in pregnancy, characterised by high blood sugar due to the hormones produced in pregnancy, usually developing in the second or third trimester and disappearing after giving birth. This is a serious condition which can lead to the baby growing larger than usual and can coincide with premature birth, stillbirth and pre-eclampsia, which are detrimental to a mother’s health.
According to the International Diabetes Federation, 1 in 7 births is affected by gestational diabetes. In addition, approximately half of women with a history of GDM go on to develop type 2 diabetes within five to ten years after delivery.
Diagnosis and Monitoring of Gestational Diabetes
Due to the severe complications that can occur with gestational diabetes, it is extremely important to accurately diagnose and monitor the condition. Tests which are commonly used to diagnose diabetes include HbA1c and glucose, including fructosamine, which due to the shorter time span, is particularly useful to evaluate the effectiveness of medication changes and to monitor the treatment of gestational diabetes.
Complications associated with gestational diabetes include diabetic ketoacidosis, a serious complication of diabetes which occurs when blood sugar levels are consistently high and insulin levels are severely low, making it essential to measure D-3-Hydroxybutyrate levels. This is a niche test which is available from Randox Reagents – find out more here.
Preventing Gestational Diabetes
As well as diagnosing and monitoring gestational diabetes, it is important that women get tested early in order to put in place measures to help avoid developing diabetes, improving quality of life for themselves and their baby. Ways in which they can do this is through adopting a healthier lifestyle in terms of monitoring diet and getting regular exercise.
Randox offer an automated adiponectin test which predicts the risk of patients developing both gestational and Type 2 Diabetes Mellitus (T2DM). Therefore, it is important to measure adiponectin before pregnancy as low concentrations are associated with reduced glucose tolerance during pregnancy and can identify women at high risk for gestational diabetes.1
Innovations in diabetes testing has led to the ability to more accurately detect risk, diagnose and manage the complications of diabetes. Randox offer a wide range of diabetes reagents in an automated biochemistry format, allowing rapid and accurate assessment for both laboratory professionals and clinicians.
Join Randox Reagents on World Diabetes Day 2017 to help spread awareness and prevent gestational diabetes in women by providing them with access to education and improve their health outcomes!
Randox are dedicated to providing the highest quality tests for diabetes diagnosis, complications monitoring and risk assessment – download our diabetes brochure to find out more about what we have to offer!
For more information, please contact us at reagents@randox.com
Sharing our preventive health message this World Diabetes Day
One of the fastest growing health threats of our times is diabetes. Type-2 diabetes is now among the most common long-term health conditions affecting people right across the globe. On World Diabetes Day we want to raise awareness of this particular condition – because it’s possible to spot warning signs and take steps to prevent it.
THE BACKGROUND
Since 1996, the number of people living with diabetes has more than doubled and type-2 diabetes is by far its most prevalent form. Though it is potentially reversible, using more advanced diagnostics, clinicians can diagnose pre-diabetes and enable patients to make lifestyle changes to avoid the condition from developing in the first place.
THE FUTURE
Adiponectin is a biomarker which can powerfully predict the development of pathologies such as Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease (CVD). This biomarker can be tested as an automated biochemistry reagent from Randox.
With the global prevalence of diabetes continually rising in adults over 18 years of age, from 4.7% in 1980 to 8.5% in 2014, adiponectin should be an integral part of every laboratory’s testing panel. Randox Adiponectin will enable physicians and clinicians to accurately evaluate more individuals, with a convenient format for routine clinical use.
When risk is identified via adiponectin measurement, it is essential for individuals to carry out lifestyle modification to lower T2DM risk. This will also help to prevent the development of cardiovascular diseases and metabolic syndrome. This indicates that Randox automated adiponectin should be a routinely run test across the world.
OUR CASE STUDY – SIR AP MCCOY
Earlier this year Sir AP McCoy came to Randox Health. After a career dedicated to becoming the world’s most successful jockey, he was never going to leave the next stage of his life to chance. It was lucky he did: our advanced test for adiponectin was within the panel of tests run and was able to identify that AP was pre-diabetic.
Don’t leave your health to chance. 70% of cases of type-2 diabetes are preventable by adopting a number of lifestyle changes, so take action today.
For further information phone the Randox PR Team on 028 9442 2413, or email randoxpr@randox.com
Randox showcases future-proofing diagnostic technology at MEDICA 2017
Randox Laboratories, the world-leading medical diagnostics manufacturer, is showcasing advancements in laboratory technology at the 2017 MEDICA – World Conference for Medicine conference, being held November 13-16 in Dusseldorf, Germany.
Unveiling its state-of-the-art interactive exhibition stand, Randox will host a series of demonstrations of its innovative analysers including the Evidence Evolution and Rx modena, and a number of exciting advances in laboratory medicine, involving increasing the test menu available to clinicians and improving the connectivity of laboratories across the world to improve overall quality.
“Through our advancements in laboratory innovation, we’re driving an industry-wide evolution” said Randox CEO, Dr Peter FitzGerald.
“Our products are leading the way in innovation and enabling laboratories to transform the way they operate. We will be hosting demonstrations of a wide range of our fully-automated analysers, which are packed with cutting-edge technology and intuitive software. The goal is to provide future-proof diagnostic technology that will create the most efficient and effective laboratories.”
Paving the way is Randox’s patented Biochip Array Technology (BAT). This multi-analyte testing platform is the product of a £250 million research and development project. The ceramic tile measuring 9×9 mm can currently run up to 49 assays simultaneously,100 assays in the near future. This innovation allows the simultaneous quantitative or qualitative detection from a wide range of analytes from a single sample. It is suitable for use in a wide range of laboratories including clinical, research, hospital, veterinary and forensic and clinical toxicology.
To enhance the benefits of BAT, Randox introduced the Evidence Evolution to its stable of immunoassay analyser platforms. The Evidence Evolution is the world’s first fully automated random-access biochip testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.
Joining the Evolution in Hall 3 stand A08 is the RX modena. This highly reliable, precise, fully automated clinical chemistry analyser can run 1200 tests per hour including ISE. When combined with its unrivalled RX series test menu, it offers a winning combination for all large, multi-disciplinary laboratories.
“We develop more new tests than any other diagnostics manufacturer, and one of the products that we’re showcasing at this year’s MEDICA is Adiponectin,” added Susan Hammond, Global Sales Manager at Randox.
“This novel biomarker is a powerful new weapon in the fight against some of the biggest health issues faced throughout the world including diabetes, cancers and cardiovascular disease. As it’s World Diabetes Day on Tuesday 14th November, it’s a great opportunity to draw attention to this array which labs can run as part of their routine testing panel.”
MEDICA attendees will also be among the first to experience the advancements delivered by the latest update for Randox’s Acusera 24.7. This online interlaboratory data management and peer reporting package is now smarter, faster and more powerful than ever before.
Acusera 24.7 is designed to help laboratories efficiently review QC data from all their lab instruments on one central platform, thereby allowing quick and easy identification of QC failures and emerging trends. Unique access to peer group data updated instantly in real-time from our global network of laboratory participants will speed up troubleshooting and help pinpoint the root cause of any QC failures by easily identifying if an issue is isolated or widespread.
The Randox team will be on hand throughout MEDICA 2017 at stand #3A08. To make an appointment in advance, contact them through the Randox MEDICA webpage.
Click here for more information on Randox, or to get in touch, phone the Randox PR Team on 028 9442 2413, or email randoxpr@randox.com
From Columbia to the UK: The trail that’s fuelling the worldwide cocaine epidemic
With the demand for cocaine in the UK rocketing, Top British Chef Gordon Ramsay has recently travelled to Columbia to the source of the problem, to learn more about this growing epidemic.
Having spent time with local farmers who own cocaine plants that resemble vineyards, and visiting Honduras, one of the most dangerous countries and known as the world’s warehouse of cocaine, he emphasized the urgent need to combat the drugs industry that is consuming this country.
Highlighted throughout the two-part series was the amount of cocaine that is being trafficked to the shores of the UK each year. Speaking with the metropolitan police who tackle up to 200 drug gangs in London alone, it was estimated that up to 300 tons of cocaine, with a street value of £10 billion, is being brought in to the country through a web of secretive routes used by drug traffickers.
Gordon commented that not only is cocaine a growing global problem, but it is one that is prevalent within the culinary world, including his own restaurants where he has been asked to dust the drug on top of soufflés as icing sugar, and found traces of this deadly drug in both his staff and customer toilets.
With the cocaine problem showing no signs of slowing down, Randox Toxicology are constantly working to develop the newest drug tests to meet the demands of the ever-growing drug market. The Evidence MultiSTAT was developed for use in non-laboratory settings such as workplaces, police stations and low throughput laboratories and to provide highly accurate qualitative as quickly as possible.
This revolutionary analyser enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs from a single patient sample, reducing the burden on current systems, the risk of adulteration and helping the fight against the cartels who control the cocaine trade in South America.
For more information on our Evidence Analysers or any of our drug panels email info@randoxtoxicology.com
We Are Randox | Parkinsonās disease documentary leads to Film Festival Award for R&D Scientist Carol Naughton
Behind the doors of Randox, ground breaking scientific research is happening.
From Alzheimer’s disease to gastro-intestinal disorders, bladder cancer to cardiovascular disease, diabetes to kidney injury, our team of R&D scientists work on pioneering research projects in the areas of health that matter most, and ultimately, they save lives.
This week, we spoke to Carol Naughton, R&D Scientist in our Randox Teoranta team in Donegal, who has recently been part of an award-winning film documentary which aims to let people into the minds, the labs and the projects of scientists working on pioneering health research like that which takes place in Randox.
The film project, called ‘Feats of Modest Valour’, focuses on the lives of three individuals with Parkinson’s disease, Brian, Tom and Milena, and on a team of scientists working to find a cure for the condition. Aiming to bridge the gap between scientists and the very people the research will have the most impact on, Carol explains how working with Parkinson’s disease sufferers was the most humbling experience of her life.
Here’s Carol’s story.
The opportunity to be involved with Feats of Modest Valour (FOMV) was a gradual one. It was towards the end of my PhD when my supervisor, Dr. Eilis Dowd was awarded a grant as part of an EU consortium called Horizon 2020, with a new initiative to cure Parkinson’s disease. One of the remits of being in receipt of this grant was a community outreach programme called Science on Screen, and because of this, the Feats of Modest Valour documentary was born. It was commissioned by the Science Foundation Ireland Centre for Research in Medical Devices (CÚRAM) and the Galway UNESCO City of Film and Galway Film Centre.
Several projects were pitched to film makers to connect with the general public, and as a result of our pitch which revolved around the gene-environment interaction and increased susceptibility in Parkinson’s disease, ISHKA Films (Alice McDowell and Mia Mullarkey) production company decided to focus on our work. As part of the Horizon 2020 grant, the brain mattrain project is focussing on the development of a new biomedical device for Parkinson’s disease which will, for the first time, target the underlying cause of Parkinson’s disease rather than purely addressing the motor symptoms.
One of the most appealing aspects of the project was the platform for engaging with the general public. There is so much fascinating research being performed for a host of diseases all over Ireland but yet there sometimes seems to be a disconnect between that and the very people who the research will have the most impact on.
This was something we were very interested in when we hosted a conference in Galway in 2014. For the NECTAR (Network for European CNS Transplantation and Restoration) conference, which brings together a unique audience of clinicians and scientists from all over the world to disseminate their research and results of clinical trials. We wanted to do something different, to broaden the scope of the conference, so we integrated a patient-oriented focus into the programme. The founder of Cure Parkinson’s UK, Tom Isaacs (1968-2017), who was diagnosed with the disease when he was only 27, attended the event and spoke passionately about trying to bridge the gap between clinicians, scientists and patients. Being part of FOMV gave us the opportunity to do this, to merge science and real life.
It helped therefore that I had been spending quite a lot of time with Brian and with people from the Parkinson’s Association of Ireland. It has several branches all over the country so I spent quite a lot of time talking with them, organising charity walks, hosting information days and securing funding for speech and language therapists for them. Considering the wealth of knowledge that you can acquire throughout the course of a PhD, it is really rewarding being able to give something back.
When I look back, easily the best part about FOMV was spending time with people with Parkinson’s disease. It is quite easy to forget the bigger picture, the reason why you set out to do research in the first place. This was an opportunity for me to interact with people who were suffering with Parkinson’s disease and talk with them and explain to them about our research. The platform for relaying scientific research to the general public is definitely an under-utilised one. For the majority of research, people do not know what is going on. When the tailor for the documentary was first shown to people, the most common response you heard back was: “I can’t believe this is happening on our backdoor,” or “That was so easy to follow and to understand,” or “Why don’t more scientists do this to explain their research to us?”
Our documentary was recently submitted to a film festival in New York called the Imagine Science Films (ISF) festival, in collaboration with the American Association for the Advancement of Science (AAAS). The select jury included Nobel prize-winning scientist Professor Martin Chalfe, and award-winning science columnist for the New York Times, Professor Carl Zimmer.
We were absolutely delighted when FOMV won The Scientist Award, which is awarded to a film that portrays, accurately and importantly inventively, the life of a scientist. The goal of this award is to encourage more scientists to create films that let people into their minds, into their labs and into their lifestyle. In addition to the top science award, FOMV was also awarded runner up People’s Choice Award. This award is presented to the documentary that receives the most audience votes during the festival.
Being part of Feats of Modest Valour was definitely one of the most humbling experiences I have ever had. I have met so many people who suffer with Parkinson’s disease and in the face of such a relentless disease, they have such incredible resolve to make the most of their lives. We tend to take so much for granted and forget to appreciate the little things. And while that sounds very clichéd, Milena, Brian and Tom are no longer in a position to do that. They live a completely clockwork existence based around the particular time when they take their medication. And even then, their days are more bad than good.
That’s why the title of the documentary ‘Feats of Modest Valour’ is based on a poem called ‘No signs of struggle,’ by an American poet named Robin Morgan, who was diagnosed with Parkinson’s disease;
“You can spot it in the provocation of a button, an arm poking at a sleeve, a balancing act at a night-time curb while negotiating the dark. Feats of such modest valour, who would suspect them to be exercises in an intimate, fierce discipline, a metaphysics of being relentlessly aware.”
Make sure to tune in to RTE One on Sunday 12th of November, when ‘Feats of Modest Valour’ is on at 10.35pm.
For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.
For current vacancies in our team, visit careers.randox.com
Randox Science Park partners with St. John Ambulance to provide emergency health response to Antrim
St. John Ambulance and global healthcare diagnostics company Randox have today announced an innovative new partnership to enhance the services provided by the first aid organisation in the Antrim area.
The Antrim unit of St. John Ambulance has moved its fleet of vehicles into Randox’s new headquarters, the Randox Science Park, to be able to provide its services from a central location in Antrim.
In addition to the new labs, offices and manufacturing space which have so far been installed at the former Massereene Barracks, St. John Ambulance will also now form part of the Randox’s Science Park renovation plans.
Dr Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“It is particularly fitting that we are now working with St. John Ambulance, given that both of our organisations are built upon a commitment to improve health and wellbeing. We’re delighted to be able to offer space for the organisation’s fleet of ambulances, and look forward to working closely with them as we enter the next phase of our Randox Science Park renovation plans.”
As part of the partnership between Randox and St. John Ambulance, St. John’s will be offering first aid training to staff within the healthcare diagnostics firm through its corporate training team.
On moving the Antrim fleet of St. John Ambulances to the Randox Science Park, Alan McClean, Unit Leader for St. John Ambulance Antrim division, said;
“Working with an organisation as reputable as Randox, from a location as central within Antrim as the Randox Science Park, will not only ensure prompt emergency response times, but will also enhance the services we offer. We want everyone in Northern Ireland to be first aid trained and to be able to receive first aid from those around them. Moving our Antrim fleet of ambulances to the Randox Science Park brings us one step closer to delivering on that aim.”
For further information, please contact our Randox PR team by emailing randoxpr@randox.com or by phoning 028 9442 2413
Alan McClean, Unit Leader of St. John Ambulance Antrim division, and Robert Huddleston, from the Randox Science Park Management Team
Diabetes ā World Diabetes Day (14th Nov 2017)
World Diabetes Day
With World Diabetes Day on Tuesday 14th November 2017, we take a look at what diabetes is and why quality control is so important.
What is Diabetes?
Diabetes is a life-long condition which occurs when the glucose level in the blood is too high because it can’t enter the body’s cells to be used as fuel. There are two types of diabetes: type 1 and type 2. They are distinct conditions and must be treated and managed differently.
Type 1 Diabetes
Type one diabetes is an autoimmune condition in which the body attacks insulin-producing cells, this causes a lack of insulin, leading to an increased blood glucose level. Around 10% of people with diabetes has type 1.
Type 2 Diabetes
A mixture of genetic and environmental factors causes type 2 diabetes. The body doesn’t make enough insulin or the insulin it does create does not work correctly, leading to a glucose build up in the blood. It’s thought that up to 58% of type 2 diabetes can be prevented or delayed through healthy lifestyle choices.
Role of Quality Control
Quality control plays a crucial role in ensuring accurate and reliable diabetes monitoring. 70% of medical decisions are based on a laboratory test result and QC is vital in ensuring the results the laboratory report are both accurate and reliable.
Want to know what makes a good HbA1c control? Read on to find out.
Clinically Relevant Levels
In the diagnosis of diabetes, glycated haemoglobin (HbA1c) in blood provides an indication of average blood glucose levels in the previous three months. HbA1c is the recommended standard of care for type 2 diabetes monitoring. HbA1c is measured using the range below:
HbA1c – Clinically Relevant Levels
| HbA1c | mmol/mol | % |
|---|---|---|
| Normal | Below 42 mmol/mol | Below 6.0% |
| Prediabetes | 42 to 47 mmol/mol | 6.0% to 6.4% |
| Diabetes | 48 mmol/mol or over | 6.5% or over |
It is important to assess the full clinical range of an assay, i.e. the range between the lowest and highest results which can be reliably reported. 48 mmol/mol is the cut-off for diabetes diagnosis, it is crucial that this can be measured accurately because any inaccuracy could mean the difference between being diagnosed and treated and not.
In terms of accreditation, ISO 15189:2012 states, ‘The laboratory should choose concentrations of control materials wherever possible, especially at or near clinical decision values, which ensure the validity of decisions made’.
Benefits of Third Party Controls
The importance of third party controls is evident. Third party controls can help identify instrument, reagent, and procedural errors. Unchecked these errors could lead to incorrect patient results, further leading to misdiagnosis.
Third party quality control material has not been designed or optimised for use with any instrument, kit, or method. This complete independence enables the quality control material to closely mirror the performance of patient samples, and in doing so, provide an unbiased, independent assessment of analytical performance across multiple platforms.
Again, in terms of accreditation, ISO 15189 states – “use of independent third party control material should be considered, either instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer.”
Many laboratories perform HbA1c testing on a dedicated machine and as a result, are not always using a third party control.
Controlling Waste
Wastage is a common issue when running HbA1c due to the pre-treatment step required for many HbA1c controls and poor stability of some controls on the market. Look out for controls with an extended open vial stability to help reduce waste and keep costs low.
How can Randox help?
To help you get your QC in check for World Diabetes Day, Randox Acusera HbA1c control contains both HbA1c and Total Haemoglobin, with a reconstituted stability of 4 weeks to reduce waste and reduce costs. To find out more about our HbA1c control visit the page using the button below or fill out the form above.
References
Diabetes: The basics. (2017). Diabetes UK. Retrieved 3 November 2017, from https://www.diabetes.org.uk/diabetes-the-basics
Khan, H et al. (2016). Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker Insights, 95. http://dx.doi.org/10.4137/bmi.s38440
Randox Health Holywood offers FREE prostate testing during Movember
Global healthcare firm Randox Health is celebrating Movember 2017 by offering free prostate health tests for every man who comes to its flagship clinic in Holywood. Prostate cancer is the most common cause of cancer in men. If it is detected early enough, it has a 90% cure rate.
During the month Randox Health hopes to raise awareness of prostate health and to encourage men to take their health into their own hands, while also raising funds for the mental health charity Inspire NI, as an additional focal aspect of men’s health.
PSA screening is not carried out routinely on the NHS as the standard test is thought to be unreliable. However the Randox Health prostate blood test, worth £130, is more advanced and can provide a more accurate diagnosis. Typical testing measures the total Prostate Specific Antigen (PSA) in the blood, however PSA can come in two forms: free and bound. Using the Randox Health PSA test, the amount of ‘free’ PSA is measured and compared to the amount of ‘bound’ PSA. Understanding this enables clients to gain a more comprehensive understanding of their prostate health.
Dr. Peter FitzGerald, Founder and Managing Director, Randox Health, commented;
“Prostate cancer is the most common cancer affecting men, and usually develops slowly. Many of us don’t know much about it and would rather not talk about it but it’s very easy to get information which can ultimately save your life. So throughout Movember I’d like to encourage men to come to our flagship clinic in Holywood to get our free test, and take control of your health. It’s our aim to help people live healthier for longer.”
Partnering with Randox Health to raise awareness of the importance of prostate checks are Garry’s Barber Shop in Holywood, the Belfast Harley Davidson’s Owners Club and the Harlandic Male Voice Choir.
The members of the choir, which was formed in 1944 by labourers of the Harland and Wolff shipyard, have this week each had their bloods taken in the Randox Health Clinic in Holywood, and in two days’ time will receive a comprehensive profile of their prostate health, enabling them to take appropriate preventive action should any problems be found. The check includes a complementary consultation where clients can discuss their results with one of Randox’s scientific experts.
Ken Banford, Chairman of the Harlandic Male Voice Choir, explained;
“As a male choir, we know all too well the reluctance to discuss our health, to open up about any issues we may be having, or even to book an appointment with our GP to do something about it. A more proactive approach to our health is needed and we hope that by doing this with Randox Health, we can encourage others to take their health into their own hands.”
Free prostate testing at Randox Health Holywood must be booked in advance. No fasting required. Results available after two working days.
To book your Free Prostate Test with Randox Health in Holywood, please call 0800 2545 130
For further information please contact the Randox PR Team by emailing randoxpr@randox.com or phoning 028 9442 2413
Staff Newsletter September / October 2017 Edition
Staff Newsletter September / October 2017 Edition
We are delighted to be able to share with you the September / October 2017 edition of our We Are Randox staff newsletter!
Click on the image for a range of company and staff news from the past two months – including the unveiling of our brand new Randox Health Mobile Clinic, attending NCLM China and Apimondia in Turkey, exciting collaborations with Ulster University and Transgene, and of course plenty of photos from our Polo events in Scotland and Bushmills!
** Please note that image links work most efficiently in your Google Chrome browser**
